Xeloda Stomach Cancer Filing Will Likely Reach EU Before FDA, Roche Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A pivotal trial found Xeloda in combination with cisplatin was non-inferior to the current standard-of-care for advanced gastric cancer, firm says.
You may also be interested in...
Roche's Xeloda Shows Significant Survival Benefit In Pancreatic Cancer
Combo therapy of Xeloda plus gemcitabine shows median survival of 7.4 months versus six months with Gemzar alone.
Xeloda Combination Studies Get Combined NCCN/Roche Support
Nine National Comprehensive Cancer Network studies are examining the cancer therapy Xeloda in solid tumors.
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.